...
首页> 外文期刊>Translational psychiatry. >Predicting treatment dropout after antidepressant initiation
【24h】

Predicting treatment dropout after antidepressant initiation

机译:预测抗抑郁发芽后的治疗辍学

获取原文

摘要

Antidepressants exhibit similar efficacy, but varying tolerability, in randomized controlled trials. Predicting tolerability in real-world clinical populations may facilitate personalization of treatment and maximize adherence. This retrospective longitudinal cohort study aimed to determine the extent to which incorporating patient history from electronic health records improved prediction of unplanned treatment discontinuation at index antidepressant prescription. Clinical data were analyzed from individuals from health networks affiliated with two large academic medical centers between March 1, 2008 and December 31, 2014. In total, the study cohorts included 51,683 patients with at least one International Classification of Diseases diagnostic code for major depressive disorder or depressive disorder not otherwise specified who initiated antidepressant treatment. Among 70,121 total medication changes, 16,665 (23.77%) of them were followed by failure to return; maximum risk was observed with paroxetine (27.71% discontinuation), and minimum with venlafaxine (20.78% discontinuation); Mantel-Haenzel χsup2/sup (8?df)?=?126.44, p?=?1.54e-23 1e-6. Models incorporating diagnostic and procedure codes and medication prescriptions improved per-medication Areas Under the Curve (AUCs) to a mean of 0.69 [0.64-0.73] (ranging from 0.62 for paroxetine to 0.80 for escitalopram), with similar performance in the second, replication health system. Machine learning applied to coded electronic health records facilitates identification of individuals at high-risk for treatment dropout following change in antidepressant medication. Such methods may assist primary care physicians and psychiatrists in the clinic to personalize antidepressant treatment on the basis not solely of efficacy, but of tolerability.
机译:抗抑郁药在随机对照试验中表现出类似的疗效,但不同的耐受性。预测现实世界临床群体中的可耐受性可以促进治疗的个性化并最大限度地提高依从性。这种回顾性的纵向队列研究旨在确定从电子健康中纳入患者历史的程度,记录了在指数抗抑郁药处的无计划治疗中断的改善预测。从2008年3月1日和2014年12月31日之间分析了来自卫生网络的个人来自卫生网络的个人。总计,研究队列包括51,683名患者至少有一个国际疾病诊断规范进行重大抑郁症或抑郁症未被指定为启动抗抑郁治疗。在70,121中,总用药变化,其中16,665名(23.77%),后来未能返回;用帕罗西汀(停止27.71%)观察到最大风险,并最低与Venlafaxine(停止20.78%); Mantel-haenzelχ 2 (8?df)?=?126.44,p?=?1.54e-23 <1e-6。将诊断和过程码和药物处方的模型改善了曲线(AUC)下的每种药物区域(AUC)的平均值为0.69 [0.64-0.73](帕罗西汀的0.62,对于EscitalOpram为0.80),在第二次复制中具有相似的性能健康系统。应用于编码电子健康记录的机器学习有助于在抗抑郁药物的变化下进行治疗辍学的高风险下的个体的鉴定。这些方法可以帮助临床中的初级护理医生和精神科医生在基于疗效的基础上对抗抑郁药物进行个性化,而是具有疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号